Pharming Group N.V. (PHAR) vs Prime Medicine (PRME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Prime Medicine (PRME) has outperformed Pharming Group N.V. (PHAR) over the past year, losing 33.6% versus a loss of 34.2%. Pharming Group N.V. is the larger company by market cap ($674.5 million vs $649.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHAR | PRME |
|---|---|---|
| Share price | $9.53 | $3.58 |
| Market cap | $674.52M | $649.33M |
| 1-day change | -1.24% | -8.21% |
| YTD return | -45.39% | +12.39% |
| 1-year return | -34.22% | -33.56% |
| 5-year return | +2.22% | — |
| P/E ratio (TTM) | 73.31 | — |
| Forward P/E | 31.04 | — |
| EPS (TTM) | $0.13 | $-1.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $21.34 | $6.65 |
| 52-week low | $9.44 | $2.67 |
| Distance from 52-week high | -55.34% | -46.17% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +260.44% | +98.60% |
| Average volume | 22.82K | 3.32M |
| Shares outstanding | 70.78M | 181.38M |
| Employees | 407 | 146 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Pharming Group N.V.
PHAR stock →Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees
About Prime Medicine
PRME stock →Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 146 employees
PHAR vs PRME FAQ
Which is bigger, Pharming Group N.V. or Prime Medicine?
Pharming Group N.V. (PHAR) is larger, with a market capitalization of $674.52M compared with $649.33M for Prime Medicine (PRME).
Which stock has performed better over the past year, PHAR or PRME?
PRME returned -33.56% over the past 12 months, compared with -34.22% for PHAR (price return, excluding dividends). Past performance does not predict future results.
Are Pharming Group N.V. and Prime Medicine in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Pharming Group N.V. and Biotechnology: Biological Products (No Diagnostic Substances) for Prime Medicine.